Monitoring Treatment Response to Erlotinib in EGFR‐mutated Non–small‐cell Lung Cancer Brain Metastases Using Serial O‐(2‐[18F]fluoroethyl)‐L‐tyrosine PET

[1]  G. Fink,et al.  Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  Karl-Josef Langen,et al.  Update on amino acid PET of brain tumours , 2018, Current opinion in neurology.

[3]  Nadim Jon Shah,et al.  Advances in neuro-oncology imaging , 2017, Nature Reviews Neurology.

[4]  J. Landsberg,et al.  Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases. , 2016, Neuro-Oncology.

[5]  Ian Law,et al.  Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. , 2016, Neuro-oncology.

[6]  Naoya Hashimoto,et al.  Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. , 2015, The Lancet. Oncology.

[7]  A. Jacobs,et al.  Response to "reply to [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma" by Hutterer et al. , 2013, Neuro-oncology.

[8]  H. Herzog,et al.  Role of O-(2-18F-Fluoroethyl)-l-Tyrosine PET for Differentiation of Local Recurrent Brain Metastasis from Radiation Necrosis , 2012, The Journal of Nuclear Medicine.

[9]  G. Fink,et al.  Imaging of Non— or Very Subtle Contrast-Enhancing Malignant Gliomas with [11C]-Methionine Positron Emission Tomography , 2011, Molecular imaging.

[10]  U. Fuhr,et al.  Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors , 2011, Clinical pharmacokinetics.

[11]  Uwe Fuhr,et al.  Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors , 2011, Clinical pharmacokinetics.

[12]  R. Boellaard,et al.  Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  V. Sturm,et al.  Stereotactic 125Iodine Brachytherapy for the Treatment of Singular Brain Metastases: Closing a Gap? , 2011, Neurosurgery.

[14]  Sang-We Kim,et al.  Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. , 2009, Lung cancer.

[15]  M. Chamberlain,et al.  Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas , 1988, Neurology.

[16]  G. Fink,et al.  Imaging of Non- or Very Subtle Contrast-Enhancing Malignant Gliomas with ( 11 C)-Methionine Positron , 2011 .